The Federal Joint Committee (G - BA) specified two appropriate comparator therapies according to the approval status: Treatment - naive patients, i.e. patients who had not been treated for HIV before, were to receive efavirenz in
combination with tenofovir and emtricitabine or in
combination with
abacavir and lamivudine.